We are live on ! Find out more
PTLA

Portola Pharmaceuticals, Inc.
PTLA

Delisted

PTLA was delisted on the 1st of July, 2020.

92 hedge funds and large institutions have $792M invested in Portola Pharmaceuticals, Inc. in 2013 Q4 according to their latest regulatory filings, with 33 funds opening new positions, 38 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

230% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 10

217% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 12

46% more capital invested

Capital invested by funds: $542M → $792M (+$250M)

33% more funds holding

Funds holding: 6992 (+23)

33% more funds holding in top 10

Funds holding in top 10: 34 (+1)

Holders
92
Holders Change
+23
Holders Change %
+33.33%
% of All Funds
2.67%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.12%
New
33
Increased
38
Reduced
12
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
1
Wellington Management Group
Massachusetts
$134M +$118M +4,873,546 +1,423%
Temasek Holdings
2
Temasek Holdings
Singapore
$109M
MAM
3
MPM Asset Management
Massachusetts
$62.9M
Fidelity Investments
4
Fidelity Investments
Massachusetts
$45.2M +$18.7M +768,500 +78%
A
5
Abingworth
United Kingdom
$32M -$122 -5 -0%
Jennison Associates
6
Jennison Associates
New York
$27.6M -$187K -7,714 -0.7%
JP Morgan Chase
7
JP Morgan Chase
New York
$26.8M +$25.3M +1,041,433 New
SAM
8
Sectoral Asset Management
Quebec, Canada
$25.8M +$851K +35,028 +4%
Vanguard Group
9
Vanguard Group
Pennsylvania
$25.2M +$12.8M +525,048 +116%
SG Americas Securities
10
SG Americas Securities
New York
$25.2M +$23.8M +977,990 New
O
11
OrbiMed
New York
$24.7M +$15.3M +630,700 +193%
FAM
12
Fred Alger Management
New York
$21.4M +$3.38M +139,190 +20%
DM
13
Deerfield Management
New York
$21.3M +$17.2M +706,227 +591%
AllianceBernstein
14
AllianceBernstein
Tennessee
$20.4M +$18.7M +771,123 +3,548%
BFA
15
BlackRock Fund Advisors
California
$18.6M +$11.5M +474,878 +191%
OTPPB
16
Ontario Teachers' Pension Plan Board
Ontario, Canada
$17.9M
T. Rowe Price Associates
17
T. Rowe Price Associates
Maryland
$16.3M -$2.73M -112,400 -15%
Franklin Resources
18
Franklin Resources
California
$16M +$2.27M +93,500 +18%
BCPEM
19
Bain Capital Public Equity Management
Massachusetts
$10.3M -$43.4M -1,785,013 -82%
EMFAT
20
Emerald Mutual Fund Advisers Trust
Pennsylvania
$8.48M +$4.24M +174,610 +120%
EA
21
Emerald Advisers
Pennsylvania
$6.69M -$287K -11,820 -4%
BCM
22
BBT Capital Management
Texas
$6.06M
BBA
23
Baker Bros. Advisors
New York
$5.78M -$1.83M -75,477 -25%
FIM
24
Fernwood Investment Management
Massachusetts
$5.68M +$5.36M +220,582 New
PI
25
Putnam Investments
Massachusetts
$5.15M

PTLA Hedge Fund Activity: Q4 2013 in Review

92 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Portola Pharmaceuticals, Inc. (PTLA) for Q4 2013, worth a combined $792M — up 46% from $542M a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new PTLA positions and 10 closed out — a net gain of 23 holders — while 38 added to existing stakes and 12 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $118M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $43.4M.

  • 92 institutional investors held Portola Pharmaceuticals, Inc. (PTLA) as of Q4 2013, up from 69 in Q3 2013.
  • Funds reported $792M of Portola Pharmaceuticals, Inc. stock for Q4 2013, up 46% quarter-over-quarter.
  • 33 funds opened new Portola Pharmaceuticals, Inc. positions in Q4 2013 and 10 closed out, a net change of +23 holders.
  • The largest Portola Pharmaceuticals, Inc. buyer in Q4 2013 was Wellington Management Group, an estimated $118M added.
  • The largest Portola Pharmaceuticals, Inc. seller in Q4 2013 was Bain Capital Public Equity Management, an estimated $43.4M sold.

Based on aggregated 13F filings for Q4 2013.